Advertisement


Carolyn Jean Presley, MD, and James L. Mulshine, MD, on New Lung Cancer CT Screening Guidelines and Treatment Burden

2015 ASCO Annual Meeting

Advertisement

James L. Mulshine, MD, of Rush University Medical Center, and Carolyn Jean Presley, MD, of Yale Cancer Center/Yale School of Medicine, discuss the burden on patients and the Medicare system as new lung cancer CT guidelines are put into effect and treatment of early-stage NSCLC increases (Abstract 7533).



Related Videos

Colorectal Cancer

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, and Axel Grothey, MD, of the Mayo Clinic, discuss the Italian-led study on trastuzumab and lapatinib in HER2-amplified metastatic colorectal as well as other colorectal cancer findings discussed at ASCO (Abstract 3508).

Breast Cancer

Nicholas C. Turner, MD, PhD, and Clifford A. Hudis, MD, on Results of the PALOMA3 Study on Hormone Receptor–Positive, HER2 Negative Metastatic Breast Cancer

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discuss fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed on prior endocrine therapy (Abstract LBA502).

Lymphoma

Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN

Andrew Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses two important lymphoma trials presented at ASCO and his views on whether their results are indeed practice-changing (Abstract 8504 and LBA8502).

Survivorship
CNS Cancers

Gregory T. Armstrong, MD, MSCE, on Late Mortality in Childhood Cancer Survivors

Gregory T. Armstrong, MD, MSCE, of St. Jude Children's Research Hospital, discusses the findings of a landmark survivorship study (Abstract LBA2).

Lymphoma

Laurie H. Sehn, MD, MPH, and James O. Armitage, MD, on Results of the GADOLIN Trial on Indolent Non-Hodgkin Lymphoma

James O. Armitage, MD, of the University of Nebraska Medical Center, and Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discuss a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).

Advertisement

Advertisement




Advertisement